Project Grant R01AI203566
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Emory University $909,998 on May 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a vaccination strategy against HIV using DNA-lipid nanoparticle technology. The research aims to induce strong and durable humoral and cellular immunity against HIV through DNA-LNP vaccination approaches that combine neutralizing antibody responses with CD8 T cell responses, including tissue-resident memory...
- The National Institute of Allergy and Infectious Diseases awarded Georgia TECH Research Corp $725,241 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop controlled-delivery HIV vaccine candidates using adjuvanted multivalent fusion peptide immunogens. The work focuses on five integrated components: safe, injectable hydrogels with tunable extended-release properties; virus-like particle platforms for multivalent antigen display;...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University $909,998 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize antibody-mediated establishment of an SIV reservoir using an art-free approach. The project, designated R01AI198034, runs through January 31, 2031, with place of performance in Atlanta, Georgia. The research employs adeno-associated virus (AAV) vectors to deliver broadly neutralizing...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $430,375 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study HIV-1 fusion competence and the regulatory roles of spacer peptide 2 and matrix protein. The research combines quantitative investigation of how spacer peptide 2 (SP2) affects viral membrane properties and fusion to elucidate SP2's role in HIV-1 fusion competence. The study addresses findings that while...
- The National Institute of Allergy and Infectious Diseases awarded Emory University a Project Grant of $153,560 on October 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research assessing the impact of HIV envelope glycoform conservation across viral clades on broadly neutralizing antibody recognition and binding breadth. The research establishes a standardized glycan similarity network using advanced glycoproteomics techniques and a novel...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $624,806 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and characterize nanotrap therapeutic vaccines for HIV treatment. The project, titled "Nanotrap Therapeutic Vaccines for HIV Virion Capture and Infected Cell Targeting" (R01AI203404), will engineer liposomal nanoparticles displaying multivalent CD4 mimetic ligands designed to capture...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $2,342,550 on May 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a combined T cell and B cell therapeutic countermeasure to achieve functional cure of HIV-1 infection. The research combines two immunological approaches: a CD8 T cell countermeasure using an integrase-deficient lentiviral vector delivering the viral GAG gene to control viremia, and a B cell countermeasure...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded San Diego Biomedical Research Institute $809,479 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered native HIV envelope glycoprotein trimers that induce broadly neutralizing antibodies (BNAbs) targeting the CD4-binding site. The research addresses two critical limitations in current HIV-1 vaccine strategies. First, existing boosting immunogens lack the stringency...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $149,190 on December 25, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antiviral compounds targeting lenacapavir-resistant HIV. The research will characterize three novel capsid effectors designed to overcome resistance-associated mutations in HIV that render lenacapavir ineffective. The work comprises three aims: biochemical and biophysical assessment of each...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $276,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate HIV-1 envelope-C3D constructs on nanoparticles for structure, function, and immunogenicity. Scripps will assess ENV-C3D fusion candidates carrying two and three copies of C3D domains per GP160 subunit (with or without Fc domain) in C57BL/6 and alloy mice. The research will measure germinal...